catalog number :
MBS241896
products full name :
Rabbit Polyclonal (IgG) to Human ERBB2 / HER2
products short name :
[ERBB2 / HER2]
products name syn :
[Anti-ERBB2 / HER2 Antibody (aa1243-1255) IHC-plus; ERBB2; C-erb B2/neu protein; CD340; HER2; Herstatin; MLN 19; HER-2; Neu; NGL; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; CD340 antigen; MLN19; p185erbB2; TKR1; Human ERBB2; HER2]
other names :
[receptor tyrosine-protein kinase erbB-2 isoform a; Receptor tyrosine-protein kinase erbB-2; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 19 protein; human epidermal growth factor receptor 2; neuro/glioblastoma derived oncogene homolog; tyrosine kinase-type cell surface receptor HER2; neuroblastoma/glioblastoma derived oncogene homolog; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; erb-b2 receptor tyrosine kinase 2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD_antigen: CD340]
products gene name :
[ERBB2]
products gene name syn :
[HER2]
other gene names :
[ERBB2; ERBB2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; HER2; MLN19; NEU; NGL; MLN 19]
uniprot entry name :
ERBB2_HUMAN
reactivity :
Human, Monkey, Mouse, Rat, Dog, Hamster, Horse, Pig. Predicted Reactivity: Bat, Bovine
specificity :
Recognizes c-erbB-2 (185kD), but not c-erbB-1(EGF-R), c-erbB-3 or c-erbB-4.
purity :
Protein A Purified
form :
10 mM PBS, pH 7.4, 0.2% BSA, 0.09% sodium azide.
storage stability :
Long term: -20°C; Short term: +4°C. Avoid repeat freeze-thaw cycles.
tested application :
Immunohistochemistry (IHC - Paraffin; IHC - Frozen), Western Blot (WB), Immunoprecipitation (IP)
app notes :
Immunohistochemistry: MBS241896 was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary antibody, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphatase-streptavidin and chromogen. The stained slides were evaluated by a pathologist to confirm staining specificity. The optimal working concentration for MBS241896 was determined to be 5 ug/ml. Western Blot: 0.5-2 ug/ml detects c-erbB-2 in RIPA lysates from A431, MDA, MCF-7, LNCap, and c-erbB-2 transfected 3T3/NIH cells. Immunoprecipitation: 4 ug immunoprecipitated c-erbB-2 from 500 ug of A431, LNCap, and c-erbB- 2 transfected 3T3/NIH RIPA lysate. IHC-paraffin: 5 ug/ml. Western Blot: 0.5-2ug/ml
image1 heading :
Immunohistochemistry (IHC)
other info1 :
Target: ERBB2/HER2. Immunogen Species: Antibody was raised against human. Immunogen: Antibody was raised against a KLH-linked peptide (AENPEYLGLDVPV) corresponding to aa1243-1255 from the human c-erbB-2/HER-2/neu oncoprotein. Percent identity by BLAST analysis: Human, Gorilla, Gibbon, Monkey, Rat, Hamster, Panda, Dog, Horse, Pig (100%); Elephant, Bat, Bovine (92%); Opossum (85%). Epitope: aa1243-1255
other info2 :
Disclaimer: Due to the highly specific nature of antibodies and antigens, we cannot predict or be held responsible with respect to how this antibody will behave in your systems. Researchers using this antibody should conduct optimization studies to achieve the most optimal result possible for their intended application. Recommended Immunohistochemistry Protocol: The following protocol is a recommendation only, and MyBioSource, Inc. makes no guarantee of the results:. Tissue Preparation: . Formalin fixation and embedding in paraffin wax. Tissue Sectioning: . Make 4-um sections and place on pre-cleaned and charged microscope slides. Heat in a tissue-dryingoven for 45 minutes at 60°C. Deparaffinization: . Wash dry slides in 3 changes of xylene - 5 minutes each @ RT. Rehydration: . Wash slides in 3 changes of 100% alcohol - 3 minutes each @ RT. Wash slides in 2 changes of 95% alcohol - 3 minutes each @ RT. Wash slides in 1 change of 80% alcohol - 3 minutes @ RT. Rinse slides in gentle running distilled water - 5 minutes @ RT. Antigen retrieval: . Steam slides in 0.01 M sodium citrate buffer, pH 6.0 at 99-100°C - 20 minutes. Remove from heat and let stand at room temperature in buffer - 20 minutes. Rinse in 1X TBS with Tween (TBST) -1 minute @ RT. Immunostaining: . (Do not allow tissues to dry at any time during the staining procedure) . Apply a universal protein block - 20 minutes @ RT. Drain protein block from slides, apply diluted primary antibody - 45 minutes @ RT. Rinse slides in 1 X TBST - 1 minute @ RT. Apply a biotinylated secondary antibody appropriate for the primary antibody - 30 minutes @ RT. Rinse slides in 1X TBST -1 minute @ RT. Apply alkaline phosphatase streptavidin - 30 minutes @ RT. Rinse slides in 1X TBST -1 minute @ RT. Apply alkaline phosphatase chromogen substrate - 30 minutes @ RT. Wash slides in distilled water - 1 minute @ RT. Dehydrate: . (This method should only be used if the chromogen substrate is alcohol insoluble (e.g. Vector Red, DAB) . Wash slides in 2 changes of 80% alcohol - 1 minute each @ RT. Wash slides in 2 changes of 95% alcohol - 1 minute each @ RT. Wash slides in 3 changes of 100% alcohol - 1 minute each @ RT. Wash slides in 3 changes of xylene - 1 minute each @ RT. Apply coverslip
products categories :
Family: Protein Kinase. Subfamily: EGF Receptor
products description :
A tyrosine kinase receptor in the EGF-receptor family. ErbB2 does not bind ligand on its own, but acts as an amplifier in heterodimers with ErbB1, (EGFR), ErbB3, or ErbB4. Amplification of the ErbB2 gene and overexpression of ErbB2 protein is associated with breast cancer (~25% of cases), and anti-ErbB2 therapeutics (e. g. Herceptin, an anti-ErbB2 monoclonal antibody) are sometimes effective in treating these cases. Overexpression of ErbB2 has also been indicated as a factor in prostate cancer.
ncbi acc num :
NP_004439.2
ncbi gb acc num :
NM_004448.3
ncbi mol weight :
97,253 Da
ncbi pathways :
Adaptive Immune System Pathway (366160); Adherens Junction Pathway (83070); Adherens Junction Pathway (481); Alpha6-Beta4 Integrin Signaling Pathway (198807); Axon Guidance Pathway (105688); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459); Central Carbon Metabolism In Cancer Pathway (1059538)
ncbi summary :
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]
uniprot summary :
HER2: a proto-oncogenic receptor tyrosine kinase of the EGFR family. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. Not activated by EGF, TGF- alpha and amphiregulin. Amplified in breast cancer. Overexpression induces constitutive activity, and the gene is amplified or overexpressed in up to 30% of breast cancers, correlating with poor survival. The antibody Herceptin is approved for treatment of metastatic breast cancer with HER2 amplification/overexpression. Somatic mutations seen in 4% of lung cancers and also in breast, gastric, ovarian cancer and glioblastoma. One SNP shows predisposition to breast and gastric cancer. Inhibitors: Herceptin, lapatinib, PKI-166, EKB-569, CI-1033. Protein type: Oncoprotein; Protein kinase, tyrosine (receptor); EC 2.7.10.1; Protein kinase, TK; Kinase, protein; Membrane protein, integral; TK group; EGFR family. Chromosomal Location of Human Ortholog: 17q12. Cellular Component: perinuclear region of cytoplasm; basolateral plasma membrane; apical plasma membrane; cytoplasm; integral to membrane; plasma membrane; endosome membrane; cytoplasmic vesicle; nucleus; receptor complex. Molecular Function: protein C-terminus binding; protein dimerization activity; identical protein binding; receptor signaling protein tyrosine kinase activity; transmembrane receptor protein tyrosine kinase activity; protein phosphatase binding; protein binding; transmembrane receptor activity; ErbB-3 class receptor binding; protein heterodimerization activity; protein-tyrosine kinase activity; growth factor binding; ATP binding. Biological Process: myelination; axon guidance; phosphoinositide 3-kinase cascade; positive regulation of cell adhesion; peptidyl-tyrosine phosphorylation; nerve growth factor receptor signaling pathway; positive regulation of translation; wound healing; heart development; protein amino acid autophosphorylation; motor axon guidance; signal transduction; protein amino acid phosphorylation; enzyme linked receptor protein signaling pathway; positive regulation of transcription from RNA polymerase I promoter; positive regulation of MAP kinase activity; cell surface receptor linked signal transduction; oligodendrocyte differentiation; neuromuscular junction development; epidermal growth factor receptor signaling pathway; negative regulation of immature T cell proliferation in the thymus; regulation of microtubule-based process; fibroblast growth factor receptor signaling pathway; phosphoinositide-mediated signaling; transcription, DNA-dependent; regulation of angiogenesis; positive regulation of cell growth; peripheral nervous system development; cell proliferation; positive regulation of transcription from RNA polymerase III promoter; innate immune response; positive regulation of protein amino acid phosphorylation; transmembrane receptor protein tyrosine kinase signaling pathway; positive regulation of epithelial cell proliferation. Disease: Gastric Cancer; Lung Cancer; Glioma Susceptibility 1